These findings suggest that the MMP-9 -1562C ] T polymorphism could be used as a marker for determining the genetic susceptibility to COPD in a Korean population.
Polymorphisms in Matrix

Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by progressive irreversible airflow limitation, which is caused by a mixture of small airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema) [1] . Although cigarette smoking is a major environmental risk factor for COPD, only a fraction of chronic smokers develop symptomatic COPD [2] , which suggests that genetic factors play an important role in its development [3, 4] .
One of the most prevailing hypotheses for the pathogenesis of COPD is an inflammatory theory, which suggests that cigarette smoke and other inhaled irritants stimulate inflammatory cells such as neutrophils and macrophages to release reactive oxygen species and a variety of proteolytic enzymes. These inflammatory events then lead to a proteinase-antiproteinase imbalance, which results in a degradation of the extracellular matrix of the lung [1, 5] . Based on this theory, the genes involved in the protease-antiprotease imbalance have attracted attention as candidates for the genetic predisposition to COPD [3, 4] .
Matrix metalloproteinases (MMP) are a family of zinc-dependent endopeptidases that degrade all the main protein components of the extracellular matrix and basement membrane [6] [7] [8] . At least 22 human MMP have been identified to date. The MMP are divided into collagenases, gelatinases, stromelysins and matrilysins based on their substrate specificity. In addition, they are also divided into 8 subgroups according to their structure, 5 of which are secreted and 3 of which are membrane-type MMP [6] [7] [8] .
It has been reported that transgenic mice that overexpress human MMP-1 (collagenase-1) in their lungs developed morphological changes similar to those observed in human pulmonary emphysema [9] . In addition, a previous study found that MMP-12 (macrophage metalloelastase) knockout mice did not develop emphysema following long-term exposure to cigarette smoke when compared to wild-type mice [10] . Furthermore, Zheng et al.
[11] demonstrated that several MMP contribute to the development of emphysema in murine lung. Moreover, several studies have shown that the expression of MMP-1 and MMP-9 is upregulated in alveolar macrophages or lung tissues from patients with COPD [12] [13] [14] . Taken together, these studies in animals and humans indicate that MMP such as MMP-1, -9 and -12 play important roles in cigarette-smoke-induced airway inflammation and the development of COPD.
Due to the important role that MMP play in the pathogenesis of COPD, several studies have investigated the association of polymorphisms in the MMP-1, -9 and -12 genes with COPD-related phenotypes; however, the results of these studies have been inconsistent [15] [16] [17] [18] [19] [20] . Therefore, we investigated the association of polymorphisms in the MMP-1, -9 and -12 genes with the risk of COPD in a Korean population. Specifically, in this study, we evaluated the MMP-1 -1607G ] GG (rs1799750), MMP-9 -1562C ] T (rs3918242) and MMP-12 N357S (rs652438A ] G) polymorphisms, which had been found to be associated with COPD-related phenotypes in the previous studies [15] [16] [17] [18] [19] [20] .
Methods
Study Population
This study included male smokers (current or former) with or without COPD from a Korean population that has been described elsewhere [21] . Briefly, the case group consisted of 301 patients who were diagnosed with COPD at the Kyungpook National University Hospital according to the criteria established by the NHLBI (National Heart, Lung, and Blood Institute)/WHO Global Initiative for COPD (GOLD) [1] . The inclusion criteria for COPD were as follows: (1) chronic respiratory symptoms and signs such as cough and dyspnea, and (2) postbronchodilator FEV 1 ! 80% of the predicted value, FEV 1 /FVC ! 70% and FEV 1 reversibility after the inhalation of 200 g salbutamol ! 12% of the prebronchodilator FEV 1 . The severity of COPD was classified by the guidelines of the GOLD in terms of the percent predicted FEV 1 : mild ( 1 80%), moderate (50-80%), severe (30-50%) or very severe ( ! 30%). Control subjects (n = 333) were selected from a pool of healthy men who visited the general health checkup center. The enrollment criteria for the controls were as follows: male, smoker, age 1 45 years, no known disease, no history of any disease and no airflow limitation. All of the cases and the controls were ethnic Koreans who resided in Daegu City or in the surrounding regions. A trained interviewer completed detailed questionnaires for each patient and each control subject. This study was approved by the institutional review board of the Kyungpook National University Hospital, and written informed consent was obtained from each participant.
Genotyping
The genotypes of the 3 polymorphisms were determined by PCR and melting-curve analysis using fluorescence-labeled hybridization probes (LightCycler; Roche Diagnostics, Mannheim, Germany) [22] . Samples that could not be scored by the LightCycler were regenotyped by direct sequencing using an ABI Prism 3700 genetic analyzer (Applied Biosystems). To confirm the genotyping results, selected PCR-amplified DNA samples were examined by DNA sequencing, and the results were 100% concordant. All genotyping analyses were blinded with respect to the case/ control status in order to ensure quality control. In addition, approximately 10% of the samples were randomly selected to be genotyped again by a different investigator, and the results were 100% concordant.
Statistical Analysis
The cases and controls were compared using the Student t test for continuous variables and a 2 test for categorical variables. The Hardy-Weinberg equilibrium for each genotyped polymorphism was tested using the goodness-of-fit test, as implemented via SAS/ Genetics. Unconditional logistic regression analyses were used to calculate the odds ratios (OR) and 95% CI, with adjustment for possible confounders (age and pack years of smoking as continuous variables). In addition to the overall association analysis, we performed a stratified analysis according to age, smoking status and severity of COPD to further explore the association between genotypes and the risk of COPD in each stratum. To assess the potential interaction between genotype and smoking (smoking status or pack years of smoking), we first included the interaction term in the logistic model. The interaction between genotype and smoking was not statistically significant; therefore, it was re-moved from the model. To correct for multiple testing, we applied a false discovery rate. A homogeneity test was conducted to compare the difference between genotype-related OR of different groups. All of the analyses were performed using the Statistical Analysis Software for Windows, version 9.1.3 (SAS Institute, Gary, N.C., USA).
Results
The baseline characteristics of the cases and controls enrolled in this study are shown in table 1 . There were no significant differences in smoking status between cases and controls. However, the age and the number of pack years were significantly higher in the cases than in the controls (age: 65. 7 
Discussion
This study has been performed as part of a series of candidate gene association studies that primarily focused on genes selected on the basis of prior knowledge of the COPD biology, including genes involved in protease-antiprotease balance, oxidative stress, the xenobiotic metabolism of toxins, and inflammatory or immune response [3, 23] . In the present study, we investigated the association between 3 polymorphisms in MMP genes (MMP-1 , -9 and -12) that had previously been reported to be associated with COPD-related phenotypes and the risk of COPD in a Korean population. Of the 3 polymorphisms evaluated, the MMP-9 -1562C ] T polymorphism was found to be significantly associated with the risk of COPD; however, the MMP-1 -1607G ] GG and MMP-12 N357S polymorphisms were not associated with the risk of COPD.
Among the polymorphisms in the MMP-1, -9 and -12 genes, we focused on the MMP-1 -1607G ] GG, MMP-9 -1562C ] T and MMP-12 N357S polymorphisms because it has been suggested that they influence gene expression or function, and because it has been reported that they are associated with COPD [15] [16] [17] [18] [19] [20] . The insertion of a G allele at position -1607 (-1607GG allele) in the promoter of the MMP-1 gene has been shown to create a binding site for the ETS-1 transcription factor, which results in enhanced gene expression [24] . In addition, it has been suggested that the MMP-9 -1562C ] T polymorphism decreases the binding affinity for a transcriptional repressor, thereby increasing MMP-9 expression [25, 26] . Although the functional effect of the MMP-12 N357S polymorphism is not known, it has been suggested that an amino acid change from acidic Asn to hydroxylic Ser alters the catalytic activity of the protein [16] .
Although a few studies have investigated the association between MMP polymorphisms and the risk of COPD, the results of these studies have been inconsistent. Minematsu et al. [15] and Ito et al. [19] investigated the association of the MMP-9 -1562C ] T polymorphism with COPD-related phenotypes in Japanese populations. They found that, although the frequency of the -1562T allele was not significantly different between COPD patients and healthy controls, COPD patients with the -1562T allele showed more severe emphysema (lower D LCO /V A and/or higher attenuation area score as indicated by chest computed tomography) when compared to patients who did not have the -1562T allele. Based on these results, these authors suggested that the -1562C ] T polymorphism acts as a genetic factor for the development of pulmonary emphysema. However, in a study investigating the association of 5 polymorphisms in the MMP genes [ MMP-1 -1607G ] GG and (CA)-repeat, MMP-9 -1562C ] T, and MMP-12 -82A ] G and N357S] with the rate of decline of lung function in mild-to-moderate COPD patients from the multicenter Lung Health Study population [16] , the MMP-9 -1562C ] T polymorphism was not found to be associated with the rate of decline of lung function, whereas the MMP-1 -1607GG allele was associated with a rapid decline of lung function. Moreover, Hersh et al. [18] reported that the MMP-1 -1607G ] GG and (CA)-repeat polymorphisms were not associated with the risk of COPD in a family study of severe early-onset COPD pedigrees and a case-control study of American Caucasians. In the present study, of the 3 polymorphisms studied ( MMP-1 -1607G ] GG, MMP-9 -1562C ] T and MMP-12 N357S), only the MMP-9 -1562C ] T polymorphism was associated with the risk of COPD. Although the reasons for the different results across studies are unclear, these inconsistencies may be due to true variability in genetic determinants among different ethnic populations, phenotypic heterogeneity, population stratification and false-negative or -positive studies [18, 27, 28] .
In the previous studies [25, 26] , the T allele of the MMP-9 -1562C ] T polymorphism has been found to increase MMP-9 expression, therefore it could be expected to increase smoking-related lung injury and the susceptibility to COPD. However, in the present study, the -1562T allele was associated with a decreased risk of COPD, which is similar to the results of several previous studies. For example, Woo et al. [29] also reported that the MMP-9 -1562T allele was protective against the development of colorectal cancer. Although it is hard to decipher the mechanism(s) responsible for the oppositely directed (flip-flop) association of the MMP-9 -1562C ] T polymorphism with COPD across studies, the different genetic backgrounds in the study populations may have been responsible for this discrepancy. The frequencies of MMP-9 single-nucleotide polymorphisms (SNPs) and the status of linkage disequilibrium between the SNPs may differ among ethnic groups; therefore, the genetic effects of the MMP-9 -1562C ] T polymorphism on the susceptibility to COPD may differ by ethnicity. In a complex polygenic disease such as COPD, it is likely that multiple genes are involved in its pathogenesis, which would result in the genetic susceptibility being dependent on the several polymorphisms acting in concert. As a result, a protective genotype in one population may increase the risk of COPD in another population due to other linked polymorphisms that exhibit stronger effects on the susceptibility to COPD. This discrepancy may be related to differences in the distribution of COPD phenotypes across studies. COPD is a heterogeneous disorder that includes obstructive bronchiolitis and emphysema. Although these COPD phenotypes share some similar pathophysiology and likely share some similar genetic determinants, there may also be divergent underlying pathways involved in their development. Accordingly, it is possible that the effects of the MMP-9 SNP on the risk of COPD will differ according to the phenotype of COPD [30, 31] .
There are several potential limitations to the present study. One such limitation is the small sample size. The sample size used in this study only enabled the identification of variants that exert a relatively large effect on the risk of COPD, while it did not have sufficient statistical power for the detection of variants that had a small effect on disease susceptibility; therefore, there might be type II errors in the analysis. In addition, the corrected p values for multiple comparisons did not reach statistical significance, which indicates that there may be type I errors. In addition, the present study was not powered to perform subgroup analyses for age, smoking status and disease severity. Accordingly, additional studies with larger sample sizes are required to confirm our findings.
Another limitation is that our study did not include the related functional assays, which limited our evaluation of the biological mechanisms involved in the observed associations between the SNPs and COPD risk. In addition, one must consider potential biases that might influence the results of hospital-based case-control studies, such as selection and information biases, which were described in our study.
In conclusion, we found that the MMP-9 -1562C ] T polymorphism contributes to the development of COPD. In addition, we found that the effect of this polymorphism is more pronounced in older individuals and heavier smokers. Taken together, these findings suggest that the MMP-9 -1562C ] T polymorphism could be used as a marker for determining the genetic susceptibility to COPD. However, due to the relatively small sample size, it is possible that our findings occurred by chance. Therefore, additional studies with larger sample sizes are required to confirm our findings. Future studies of other MMP-9 variants and their biologic function are also needed to understand the role of MMP-9 polymorphisms in the risk of COPD.
